EDP Sciences logo
Open Access
Ann Toxicol Anal
Volume 22, Numéro 3, 2010
Page(s) 115 - 121
DOI https://doi.org/10.1051/ata/2010017
Publié en ligne 6 juillet 2010
  1. Huang D, Okada K, Komori C, Itoi E, Suzuki T. Enhanced antitumor activity of ultrasonic irradiation in the presence of new quinolone antibiotics in vitro. Cancer Sci. 2004; 95: 845–849. [CrossRef] [PubMed] [Google Scholar]
  2. Vainchtein LD, Rosing H, Mirejovsky D, Lenaz L, Schellens JH, Beijnen JH. Stability experiments in human urine with EO9 (apaziquone): a novel anticancer agent for the intravesical treatment of bladder cancer. J Pharm Biomed Anal. 2007; 43: 285–292. [CrossRef] [PubMed] [Google Scholar]
  3. Bracci L, Moschella F, Sestili P, La Sorsa V, Valentini M, Canini I, Baccarini S, Maccari S, Ramoni C, Belardelli F, Proietti E. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin Cancer Res. 2007; 13: 644–653. [CrossRef] [PubMed] [Google Scholar]
  4. Kiss L, Mangelinckx S, Fülöp F, De Kimpe N. Convenient synthesis of trans-beta-amino carboxylic esters with an azetidine skeleton via rearrangement of beta, gamma-aziridino alpha-amino esters. Org Lett. 2007; 9: 4399–402. [CrossRef] [PubMed] [Google Scholar]
  5. Warner DL, Hibberd AM, Kalman M, Klapars A, Vedejs E. N-Silyl Protecting Groups for Labile Aziridines: Application toward the Synthesis of N-H Aziridinomitosenes. Cancer Immunol Immunother. 2007; 32: 311–314. [Google Scholar]
  6. Kowalczyk-Bronisz SH, Zabska R. Studies on the derivatives of aziridine. I. Synthesis and immunopharmacological analysis of amides of alpha- aziridinyl beta-/p- chlorobenzoyl/- propionic acid. Arch Immunol Ther Exp. 1986; 34: 333–350. [Google Scholar]
  7. Hanessian S, Cantin LD. The synthesis of enantiomerically pure disubstituted aziridines and N-alkoxy aziridines. Tetrahedron Lett. 2000; 41: 787–790. [CrossRef] [Google Scholar]
  8. Srikrishnan T. Structural studies of immunomodulators. Part 2: crystal structure and conformation of azimexon (BM 12.531) an immunostimulant and an anti-tumor drug. Anticancer Drug Des. 1990; 5: 213–220. [PubMed] [Google Scholar]
  9. Becker U. Immunomodulating effects of BM 12.531 in animals and tolerance in man. Cancer Treat Rev. 1978; 11: 1987–1996. [Google Scholar]
  10. Baier J, Neumann HA, Ricken O. No inhibition of interferon gamma release in human lymphocytes by Ciamexone. Cancer immunol immunother. 1991; 62: 1987–1996. [Google Scholar]
  11. Siwy M, Sek D, Kaczmarczyk B, Wietrzyk J, Nasulewicz A, Opolski A. Synthesis and in vitro antiproliferative activity of new 1,3-(oxytetraethylenoxy)-cyclotriphosphazene derivatives. Anticancer Res. 2007; 27: 1553–1558. [PubMed] [Google Scholar]
  12. Medjahed W, Tabet Zalta A, Kajima Mulengi J, Baba Ahmed FZ, Merzouk H. The synthesis of n-acyl-2-hydroxyméthyl aziridines of biological interest. Tetrahedron Lett. 2004; 45: 1211–1213. [CrossRef] [Google Scholar]
  13. Baba Ahmed F, Medjahed W, Merzouk H, Kajima Mulengi J, Belleville J, Prost J. Effects of N-acyl-2-Hydroxyméthyl Aziridines on Proliferative Responses of Human Lymphocytes Stimulated by Mitogens. Gen Physiol Biophys. 2006; 25: 277–287. [PubMed] [Google Scholar]
  14. Baba Ahmed FZ, Bouanane S, Merzouk SA, Merzouk H, Medjahed W, Kajima Mulengi J, Prost J. 2-hydroxy-méthyl-1 (N-phtaloyltryptophyl) aziridine stimule la prolifération in vitro des lymphocytes humains et la sécrétion des interleukines. Pathologie Biologie. 2008; 56: 137–142. [CrossRef] [Google Scholar]
  15. CCPA, Conseil Canadien de Protection des Animaux (1993) Manuel sur le soin et l’utilisation des animaux d’expérimentation. Ottawa. 1993; 1: 232–256. [Google Scholar]
  16. OCDE. Guidance Document on the Recognition, Assessment and Use of Clinical Signs as Humane Endpoints for Experimental Animals Used in Safety Evaluation. Environmental Health and Safety Monograph Series on Testing and Assessment, 2000: 19. [Google Scholar]
  17. OCDE. Guidance document on Acute Oral toxicity. Environmental Health and Safety Monograph Series on testing and assessment, 2001: 24. [Google Scholar]
  18. Claude A. Investigations toxicologiques pour un nouveau médicament. In: Giroud JP et coll. (coordinateurs). Pharmacologie clinique/bases de la thérapeutique. 2e edition. Paris: Expansion scientifique française, 1988: 3–14. [Google Scholar]
  19. Sirwal IA, Banday KA, Reshi AR, Bhat MA, Wani MM. Estimation of Glomerular Filteration Rate (GFR). JK Science. 2004; 6: 121–123. [Google Scholar]
  20. Kew MC. Serum aminotransferase concentration as evidence of hepatocellular damage. Lancet. 2000; 355: 591–592. [CrossRef] [PubMed] [Google Scholar]
  21. Afssaps. Essais cliniques de première administration à l’homme, en dose unique d’un médicament expérimental. Choix de la première dose, de la progression de dose et protocole d’administrations aux volontaires. Agence Française Sécurité Sanitaire, 2006: 1–5. [Google Scholar]